Bainbridge Health

bainbridgehealth.com

Medication is one of the most dangerous, costly, and complex things in the hospital. Our mission is to provide clinician-friendly technology and support services to save money, save time, and make medication safer. Designed by clinicians for clinicians, our goal is to help clinical and pharmacy leaders stay focused on decision-making–not data clerking– by making medication data easier to access, analyze, and act on.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

KITE AND SHORELINE BIOSCIENCES FORM STRATEGIC PARTNERSHIP TO DEVELOP NOVEL ALLOGENEIC CELL THERAPIES

Kite, Shoreline Biosciences | June 18, 2021

news image

Kite, a Gilead Company, and Shoreline Biosciences, Inc., a biotechnology firm developing intelligently designed allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and Macrophage cellular immunotherapies achieved from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, announced a strategic partnership today to develop novel cell therapies across a variety of indications. The collaboration will combine Shoreline’s profound experi...

Read More

Medical

SOSEI HEPTARES' COVID-19 PROGRAM IDENTIFIES POTENT BROAD SPECTRUM ANTI-VIRAL SMALL MOLECULES FOR FURTHER DEVELOPMENT

Sosei Heptares | November 21, 2020

news image

Sosei Group Corporation ("the Company") (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19.The program was initiated in April 2020. To date, the Company has applied its world-leading structure-based drug design (SBDD) capabilities and cutting-edge technologies to precision-design new inhibitors of the SARS-CoV-2 Mpro protease, which plays a crucial role in ...

Read More

Medical

DNA-ENCODED LIBRARIES (DELS) AND NANOBRET TARGET ENGAGEMENT ASSAYS ACCELERATE DRUG DISCOVERY

Businesswire | August 03, 2023

news image

A new study demonstrates how the combination of DNA-encoded libraries (DELs) and NanoBRET Target Engagement technology can accelerate early-stage drug discovery. Reported in Cell Chemical Biology, researchers from Promega Corporation and WuXi AppTec generated new chemical probes from molecules identified through a DEL screen. This research opens new opportunities to develop novel NanoBRET Target Engagement Assays aimed at many understudied classes of proteins, rapidly accelerating “h...

Read More

Cell and Gene Therapy

CASMA THERAPEUTICS RAISES $46.0 M IN SERIES C FUNDING

Casma Therapeutics, Inc. | November 21, 2022

news image

Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono Venture Investment. Current investors Eventide Asset Management, LLC, Schroders Capital, The Column Group, Third Rock Ventures, and other funds also particip...

Read More
news image

Cell and Gene Therapy

KITE AND SHORELINE BIOSCIENCES FORM STRATEGIC PARTNERSHIP TO DEVELOP NOVEL ALLOGENEIC CELL THERAPIES

Kite, Shoreline Biosciences | June 18, 2021

Kite, a Gilead Company, and Shoreline Biosciences, Inc., a biotechnology firm developing intelligently designed allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and Macrophage cellular immunotherapies achieved from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, announced a strategic partnership today to develop novel cell therapies across a variety of indications. The collaboration will combine Shoreline’s profound experi...

Read More
news image

Medical

SOSEI HEPTARES' COVID-19 PROGRAM IDENTIFIES POTENT BROAD SPECTRUM ANTI-VIRAL SMALL MOLECULES FOR FURTHER DEVELOPMENT

Sosei Heptares | November 21, 2020

Sosei Group Corporation ("the Company") (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19.The program was initiated in April 2020. To date, the Company has applied its world-leading structure-based drug design (SBDD) capabilities and cutting-edge technologies to precision-design new inhibitors of the SARS-CoV-2 Mpro protease, which plays a crucial role in ...

Read More
news image

Medical

DNA-ENCODED LIBRARIES (DELS) AND NANOBRET TARGET ENGAGEMENT ASSAYS ACCELERATE DRUG DISCOVERY

Businesswire | August 03, 2023

A new study demonstrates how the combination of DNA-encoded libraries (DELs) and NanoBRET Target Engagement technology can accelerate early-stage drug discovery. Reported in Cell Chemical Biology, researchers from Promega Corporation and WuXi AppTec generated new chemical probes from molecules identified through a DEL screen. This research opens new opportunities to develop novel NanoBRET Target Engagement Assays aimed at many understudied classes of proteins, rapidly accelerating “h...

Read More
news image

Cell and Gene Therapy

CASMA THERAPEUTICS RAISES $46.0 M IN SERIES C FUNDING

Casma Therapeutics, Inc. | November 21, 2022

Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono Venture Investment. Current investors Eventide Asset Management, LLC, Schroders Capital, The Column Group, Third Rock Ventures, and other funds also particip...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

resource image

Cell and Gene Therapy

VIA Thaw™ automated dry thawer

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us